At a glance
| Sequence shorthand | Pal-KTTKS |
|---|---|
| Trade context | Original Matrixyl |
| Clinical design | Randomized split-face comparison |
| Studied population | 93 women with photoaged facial skin |
| Endpoint | Fine-line and wrinkle appearance |
Overview
Palmitoyl pentapeptide-4 links a fatty-acid chain to the five-amino-acid sequence lysine-threonine-threonine-lysine-serine, usually shortened to KTTKS. Research on that sequence began with extracellular-matrix signaling in cultured cells. Adding the palmitoyl group changes the molecule’s formulation properties and distinguishes the cosmetic ingredient from the unmodified peptide. The human evidence is stronger than a supplier claim alone because a randomized, blinded, vehicle-controlled study exists. Even so, a successful study of one moisturizer does not establish equal performance in every serum, permanent reversal of aging, or a treatment for scars and wounds.
How it works
KTTKS is a fragment associated with type I procollagen and has been studied as a signal influencing matrix production. Original cell experiments found effects on collagen and fibronectin synthesis. Palmitoylation was used to adapt the peptide for topical cosmetic formulation. The resulting concept is a signaling ingredient, not replacement collagen physically filling the dermis; penetration and final-product composition still determine what exposure is achieved.
The split-face trial
A 12-week double-blind study in 93 women compared a moisturizer containing pal-KTTKS with the same vehicle on the other side of the face. Technical image analysis and expert grading found improvement in fine lines and wrinkles relative to the control. The matching vehicle is a strength because it helps separate peptide-associated effects from ordinary moisturization.
Supporting sources [1]
Cell findings support a rationale, not every claim
The original KTTKS study examined extracellular-matrix production in cultured mesenchymal cells. It helps explain why the sequence was investigated, but does not prove systemic repair or effects on all skin structures. The human cosmetic trial is the more direct evidence for visible facial outcomes.
Supporting sources [2]
Interpret the finished formulation
The clinical formulation was described as well tolerated, but that does not establish zero irritation with all products or unlimited exposure. Cosmetic status is not FDA drug approval. Brand-family similarity should not obscure that other Matrixyl products contain different peptides and require their own evidence.
Reading this profile
Jurisdiction: United States; status and indications may differ elsewhere. Molecular class: Palmitoylated collagen-fragment pentapeptide.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Topical palmitoyl pentapeptide in photoaged facial skin: controlled split-face study ↗Clinical trial source · Checked 2026-10-27
- KTTKS from type I procollagen and extracellular-matrix production ↗Original research · Checked 2026-10-27
- Croda: original Matrixyl ingredient identity ↗Manufacturer / sponsor · Checked 2026-10-27
- FDA: authority over cosmetics and the distinction from drug approval ↗Regulatory source · Checked 2026-10-27